People: CytomX Therapeutics Inc (CTMX.OQ)
Kavanaugh, W. Michael
Mr. W. Michael Kavanaugh, M.D. serves as a Chief Scientific Officer and Head - Research and Non-Clinical Development of the company. Since January 2015. Prior to joining us, Dr. Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics, Inc. From February 2009 to December 2014, Dr. Kavanaugh held multiple positions in research and development at Five Prime Therapeutics, Inc. and led the growth of its therapeutic pipeline. Prior to that, Dr. Kavanaugh served as vice president of Novartis Vaccines & Diagnostics, Inc. and executive director of Oncology Biologics in the Novartis Institutes of Biomedical Research. He joined Novartis as part of its acquisition of the Chiron Corporation in 2006, where he held positions as vice president and head of antibody and protein therapeutics research. Dr. Kavanaugh received his M.D. from Vanderbilt University and his B.S. in molecular biochemistry and biophysics from Yale University. He completed training in internal medicine, cardiovascular disease and molecular and cellular biology at University of California, San Francisco, and the Cardiovascular Research Institute. Dr. Kavanaugh also currently serves as an attending staff physician at the San Francisco Veterans Administration Medical Center and as an associate clinical professor of Medicine at University of California, San Francisco.
|Total Annual Compensation, USD||395,117|
|Restricted Stock Award, USD||--|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||987,139|
|Fiscal Year Total, USD||1,382,260|